Skip to main content
IMS Events Main banner

    Joshua Rivera, PhD

    Post-Doctoral Researcher
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Dr. Joshua Rivera is a Postdoctoral Fellow at Dana-Farber Cancer Institute and Harvard Medical School, where he specializes in single-cell data science and computational oncology. His research leverages cutting-edge computational approaches to better understand the transcriptional and regulatory mechanisms that drive multiple myeloma progression and therapeutic resistance.

    Dr. Rivera’s work focuses on integrating single-cell RNA sequencing, ATAC-seq, and network biology to reconstruct transcription factor regulatory networks at both the patient-specific and consensus levels. By identifying high-confidence transcription factors and regulatory modules that are conserved across patients, his research aims to uncover core dependencies in hyperdiploid and translocation subtypes of multiple myeloma. These efforts are directed toward advancing our understanding of disease evolution and informing the design of novel therapeutic strategies that can target shared regulatory vulnerabilities.

    In parallel, Dr. Rivera is leading the development of a foundational single-cell multi-omic framework that harmonizes large-scale datasets from both healthy and malignant bone marrow. By integrating healthy donor and patient data, this framework provides a unique opportunity to contextualize malignant programs within a baseline of immune system function. The resulting models are expected to yield new insights into how immune dysfunction contributes to disease progression and may serve as a foundation for the development of next-generation precision medicine approaches.

    At The Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Dr. Rivera’s research bridges computational biology, systems immunology, and translational oncology. His long-term goal is to use single-cell and multi-omic technologies to identify molecular mechanisms of disease that can be exploited to guide more effective and durable treatments for patients with multiple myeloma and other hematologic malignancies.

    Disclosure information not submitted.

    Presentation(s):